Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast Cancer

Active, not recruiting

Conditions: Breast Cancer

First Posted Date: 2022-10-26

Last Posted Date: 2023-04-04

Lead Sponsor: Fudan University

Target Recruit Count: 150

Registration Number: NCT05594082

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma

Early Phase 1

Recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Behavioral: PK Blood Collection
Drug: CAR
Drug: TCR

First Posted Date: 2022-10-20

Last Posted Date: 2024-11-11

Lead Sponsor: Fudan University

Target Recruit Count: 24

Registration Number: NCT05587543

Locations: 🇨🇳
Fudan University, Shanghai, China

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Phase 2

Recruiting

Conditions: Breast Neoplasm
HER2-positive Breast Cancer
HER2-negative Breast Cancer
Hormone Receptor Positive Tumor
Breast Cancer
Breast Tumors
Hormone Receptor Negative Tumor
Triple-Negative Breast Cancer (TNBC)
Locally Advanced Breast Cancer
Early-stage Breast Cancer

Interventions: Drug: Nab paclitaxel
Drug: Camrelizumab
Drug: Pyrotinib
Drug: SHR-A1811
Drug: SHR-A1921
Drug: Pertuzumab
Drug: SHR-1316
Drug: Dalpiciclib
Drug: Trastuzumab
Drug: Goserelin
Drug: Carboplatin
Drug: Apatinib
Drug: Letrozole
Drug: Famitinib
Drug: Epirubicin
Drug: Cyclophosphamide
Drug: Fluzoparib

First Posted Date: 2022-10-17

Last Posted Date: 2024-12-27

Lead Sponsor: Fudan University

Target Recruit Count: 716

Registration Number: NCT05582499

Locations: 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China

Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)

Phase 2

Not yet recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Trastuzumab
Drug: pyrotinib
Drug: Dalpiciclib
Drug: fulvestrant

First Posted Date: 2022-10-13

Last Posted Date: 2022-10-13

Lead Sponsor: Fudan University

Target Recruit Count: 126

Registration Number: NCT05577923

Locations: 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China

Novel Therapy Target in Metastatic Prostate Cancer

Recruiting

Conditions: Prostate Neoplasms

Interventions: Other: Tissue

First Posted Date: 2022-10-13

Last Posted Date: 2025-06-05

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT05577689

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Acute Health Effects of High Temperature Exposure

Not Applicable

Active, not recruiting

Conditions: Cognitive Function
Respiratory System
Cardiovascular System

Interventions: Other: moderate temperature (22℃) group
Other: high temperature (32℃) group

First Posted Date: 2022-10-12

Last Posted Date: 2025-02-26

Lead Sponsor: Fudan University

Target Recruit Count: 40

Registration Number: NCT05575752

Locations: 🇨🇳
Department of Environmental Health, School of Public Health, Fudan University, Shanghai, Shanghai, China

Peri-operative Foot CT Perfusion in CLI Patients

Active, not recruiting

Conditions: Critical Limb Ischemia

First Posted Date: 2022-10-12

Last Posted Date: 2022-10-12

Lead Sponsor: Fudan University

Target Recruit Count: 90

Registration Number: NCT05575778

Locations: 🇨🇳
Hua Dong Hospital Affiliated to Fu Dan University, Shanghai, China

Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer

Phase 1

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Dalpiciclib
Drug: Fulvestrant
Drug: Pertuzumab
Drug: Trastuzumab

First Posted Date: 2022-10-12

Last Posted Date: 2024-02-26

Lead Sponsor: Fudan University

Target Recruit Count: 72

Registration Number: NCT05574881

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer

Phase 1

Recruiting

Conditions: Advanced/ Metastatic Her-2 Positive Breast Cancer

Interventions: Drug: GQ1001+pyrotinib
Drug: pyrotinib+capecitabine

First Posted Date: 2022-10-12

Last Posted Date: 2024-02-26

Lead Sponsor: Fudan University

Target Recruit Count: 75

Registration Number: NCT05575804

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

Completed

Conditions: Breast Cancer

Interventions: Drug: Pertuzumab Plus Trastuzumab
Drug: Pyrotinib Plus Trastuzumab

First Posted Date: 2022-10-10

Last Posted Date: 2024-02-26

Lead Sponsor: Fudan University

Target Recruit Count: 333

Registration Number: NCT05572645

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy